210 related articles for article (PubMed ID: 17607758)
1. Metabolic syndrome and cardiovascular disease: challenges and opportunities.
Cooper-DeHoff RM; Pepine CJ
Clin Cardiol; 2007 Dec; 30(12):593-7. PubMed ID: 17607758
[TBL] [Abstract][Full Text] [Related]
2. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome.
Otani H
Antioxid Redox Signal; 2011 Oct; 15(7):1911-26. PubMed ID: 21126197
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological approach to cardiovascular risk in metabolic syndrome.
Bellis A; Trimarco B
J Cardiovasc Med (Hagerstown); 2013 Jun; 14(6):403-9. PubMed ID: 23337396
[TBL] [Abstract][Full Text] [Related]
5. The metabolic syndrome in hypertension: European society of hypertension position statement.
Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G;
J Hypertens; 2008 Oct; 26(10):1891-900. PubMed ID: 18806611
[TBL] [Abstract][Full Text] [Related]
6. New treatment strategies for patients with hypertension and insulin resistance.
Kurtz TW
Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
[TBL] [Abstract][Full Text] [Related]
7. Management of the metabolic syndrome.
Grant RW; Meigs JB
Panminerva Med; 2005 Dec; 47(4):219-28. PubMed ID: 16489321
[TBL] [Abstract][Full Text] [Related]
8. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
Boucek P
Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
[TBL] [Abstract][Full Text] [Related]
9. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
10. Management issues in the metabolic syndrome.
Deedwania PC; Gupta R
J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
[TBL] [Abstract][Full Text] [Related]
11. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.
Petersen JL; McGuire DK
Diab Vasc Dis Res; 2005 Feb; 2(1):9-15. PubMed ID: 16305067
[TBL] [Abstract][Full Text] [Related]
12. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
Rayner B
Curr Med Res Opin; 2004 Mar; 20(3):359-67. PubMed ID: 15025845
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
14. Metabolic syndrome: treatment of hypertensive patients.
Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
[TBL] [Abstract][Full Text] [Related]
15. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
16. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
Leiter LA; Lewanczuk RZ
Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes.
Macfarlane DP; Paterson KR; Fisher M
Diabetes Obes Metab; 2008 Jul; 10(7):533-44. PubMed ID: 18248492
[TBL] [Abstract][Full Text] [Related]
18. Metabolic syndrome: nature, therapeutic solutions and options.
Onat A
Expert Opin Pharmacother; 2011 Aug; 12(12):1887-1900. PubMed ID: 21756201
[TBL] [Abstract][Full Text] [Related]
19. PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome.
Fernandez AZ
Curr Opin Investig Drugs; 2004 Sep; 5(9):936-40. PubMed ID: 15503647
[TBL] [Abstract][Full Text] [Related]
20. Management of the metabolic syndrome.
Scheen AJ
Minerva Endocrinol; 2004 Jun; 29(2):31-45. PubMed ID: 15257254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
